Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

forbes.com - Matt Lowe - Pharma Believes In AI, But The Foundation Is Failing
Pharma Believes In AI, But The Foundation Is Failing
Forbes

Matt Lowe, chief strategy officer for MasterControl. The pharmaceutical industry's AI market is projected to grow from roughly $4 billion to $25.7 billion by 2030. Despite this surge, medicine makers have yet to see substantially shorter…

forbes.com - Kamya Elawadhi - How Pharma Marketing Can Evolve Beyond Audience Targeting
How Pharma Marketing Can Evolve Beyond Audience Targeting
Forbes

Kamya Elawadhi is Co-Founder and President at Doceree. For the better part of a decade, pharma marketing has pursued one goal above all others: Know the audience. Look-alike models were built on claims data. National provider identifier-level…

bloomberg.com - Amber Tong - Big Pharma Is Hooked on Chinese Licensing Deals
Big Pharma Is Hooked on Chinese Licensing Deals
Bloomberg

Merck & Co. executives were excited. They were working on a drug that had the potential to become a “cornerstone” treatment for cancer, with 17 late-stage trials pitting it against lung, breast and other tumors. “It is one of…

law360.com - Jeff Overley - At DC Circ., Pharma's Latest Pricing Loss Has Silver Linings
At DC Circ., Pharma's Latest Pricing Loss Has Silver Linings
Law360

The pharmaceutical industry's far-flung crusade against Medicare's new negotiation powers suffered a fresh setback Tuesday as the D.C. Circuit joined sister circuits in upholding the landmark pricing program, but the defeat... To view the full…

fool.com - Sara Appino - Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI?
Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI?
The Motley Fool

The VanEck Pharmaceutical ETF (PPH +1.86%) offers concentrated exposure to established global drugmakers and higher yields, while the State Street SPDR S&P Biotech ETF (XBI -0.20%) provides a diversified, higher-volatility play on smaller-cap…

econotimes.com - Riza Dagoc - Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook
EconoTimes

Schott Pharma shares climbed more than 4% in early Frankfurt trading after Barclays upgraded the pharmaceutical packaging company to Overweight, citing improving fundamentals and expectations for accelerating earnings growth. Barclays believes…

newswire.ca - Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
CNW

Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad…

thehindubusinessline.com - Invesco MF launches India Pharma and Healthcare NFO
Invesco MF launches India Pharma and Healthcare NFO
BusinessLine

Invesco Mutual Fund has launched India Pharma and Healthcare Fund which will invest across pharmaceutical companies, hospitals, diagnostics, contract development and manufacturing organisations, contract research organisations, medical devices…

247wallst.com - Trey Thoelcke - Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
24/7 Wall St

KLRA trades 29% below its IPO high but holds $1.17 billion in cash and carries a $42 analyst consensus price target. Merck's looming Keytruda revenue cliff and Novo Nordisk's need to defend Wegovy dominance make both natural buyers of Kailera's…

marketbeat.com - Ascendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime Purchases 2,000 Shares of Stock
Ascendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime Purchases 2,000 Shares of Stock
MarketBeat

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) Director Jean Jacques Bienaime purchased 2,000 shares of the company's stock in a transaction on Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, for a total…

forbes.com - Nataliya Andreychuk - ​​Idea First, Customer Second: The Mindset That Drives Innovation
​​Idea First, Customer Second: The Mindset That Drives Innovation
Forbes

Nataliya Andreychuk is the CEO of Viseven. She is a leading digital transformation evangelist for the pharma and life sciences industries. After years of conversations with pharmaceutical industry leaders across markets, I've come to a conclusion…

rediff.com - Nandita Malik - Indian Stock Market Declines: Crude Oil Spike, US Bond Yields, West Asia Tensions Impact Sentiment
Indian Stock Market Declines: Crude Oil Spike, US Bond Yields, West Asia Tensions Impact Sentiment
Rediff.com

Indian stock markets, including the Sensex and Nifty, opened lower as a significant jump in Brent crude oil prices above $91 per barrel, fuelled by escalating West Asia tensions and rising US bond yields, dampened investor sentiment. Indian…

zerohedge.com - Tyler Durden - 'Sea Of Red': Futures Slide As Market Wakes Up To Soaring Bond Yields And Diesel Prices
'Sea Of Red': Futures Slide As Market Wakes Up To Soaring Bond Yields And Diesel Prices
Zero Hedge

US futures are a 'sea of red' (as Bloomberg describes it) in early trading as thin summer volumes persist, with the wrong kind of inflation coming to the fore and Monday's tech selloff weighing on sentiment despite bullish AI news. The recent…

cnbc.com - Brad Quick - The startup using AI to help rare disease families develop custom treatments
The startup using AI to help rare disease families develop custom treatments
CNBC

Nome is building an AI-powered drug development service for ultra-rare disease patients, helping families identify potential treatments and map out a path from diagnosis to clinical development. The startup targets patient groups often overlooked…

thehindu.com - Pti - Stock Markets decline in early trade as crude oil jumps to $91 per barrel
Stock Markets decline in early trade as crude oil jumps to $91 per barrel
The Hindu

Market benchmark indices Sensex and Nifty declined in early trade on Tuesday (August 18, 2026) as elevated crude oil prices and rising tensions in West Asia weighed heavily on investors' sentiment. The 30-share BSE Sensex was down 278.32 points to…

Receive a Daily briefing on Pharma Industry News

Get Started